Close Menu

Think Smart

Deals with biotech companies are becoming more important as pharmaceutical companies go through restructuring, writes John Carroll at FierceBiotech. "We've been seeing a lot more smart biotechs doing licensing deals at an early stage this year. Preclinical pacts are not at all uncommon," he says. However, Carroll notes that deal terminations by pharma companies are occurring at earlier stages.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Bloomberg reports that the DNA-for-cash deal reported in Kentucky might be a more widespread scam.

St. Jude Children's Research Hospital scientists have treated infants with X-linked severe combined immunodeficiency using gene therapy in an early phase study.

St. Louis Public Radio reports that some African Americans are turning to DNA ancestry testing to help guide genealogical searches.

In Nature this week: a genomic analysis of the snailfish Pseudoliparis swirei, ancient DNA analysis gives insight into the introduction of farming to England, and more.